Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies...
Main Authors: | Magalie Dosset, Elodie Lauret-Marie Joseph, Thaiz Rivera Vargas, Lionel Apetoh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/7/1727 |
Similar Items
-
Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments
by: Adrien Procureur, et al.
Published: (2021-02-01) -
Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma
by: Siwei Yang, et al.
Published: (2024-04-01) -
Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma
by: Wendy W. L. Lee, et al.
Published: (2024-04-01) -
Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis
by: Xiangyu Chen, et al.
Published: (2024-02-01) -
Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
by: Hui Dong, et al.
Published: (2023-01-01)